The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shchukin I.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Koltsov I.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Fidler M.S.

Pirogov Russian National Research Medical University (Pirogov University)

Glukhareva A.P.

Pirogov Russian National Research Medical University (Pirogov University)

Neurocytoprotection advances in reperfusion therapy

Authors:

Shchukin I.A., Koltsov I.A., Fidler M.S., Glukhareva A.P.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12‑2): 75‑88

DOI: 10.17116/jnevro202412412275

Views: 463

Downloaded: 3

Buy for 300₽
Contact the author
Table of contents

NEUROCYTOPROTECTION ADVANCES IN REPERFUSION THERAPY
NEUROCYTOPROTECTION ADVANCES IN REPERFUSION THERAPY

To cite this article:

Shchukin IA, Koltsov IA, Fidler MS, Glukhareva AP. Neurocytoprotection advances in reperfusion therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(12‑2):75‑88. (In Russ.)
https://doi.org/10.17116/jnevro202412412275

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
Brain-derived neurotrophic factor in the acute and early reco­very period of ischemic stroke: the role of nocturnal hypo­xemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):72-78
Indi­cators of cognitive impairment of varying seve­rity in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):14-20
Repeated ischemic stro­kes due to infe­ctious arte­ritis of both inte­rnal caro­tid and basi­lar arte­ries as a complication of sphe­noiditis and otitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):31-37
Cases of successful thro­mbus extraction in ischemic stroke asso­ciated with the new coro­navirus infe­ction COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):38-46
On the issue of opti­mizing protein and energy supply for patients with acute cere­brovascular acci­dent. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):51-55
Place of oligopeptide H-Met-Glu-His-Phe-Pro-Gly-Pro-OH in the therapy and reha­bilitation of patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8-2):56-63
Methods of cost-effectiveness evaluation of endo­vascular patent fora­men ovale closure for seco­ndary prevention of cryptogenic stroke. Russian Journal of Preventive Medi­cine. 2024;(6):105-110
Possibilities of physiotherapy in glaucomatous optic neuropathy after glaucoma surgery. Russian Annals of Ophthalmology. 2024;(3):88-94
Comparison of the effe­ctiveness of non-immunogenic staphylokinase and alte­plase for intravenous thro­mbolysis in ischemic stroke: analysis of hospital regi­stry data. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):139-144
Pharmacological effe­cts of fonturacetam (Actitropil) and prospects for its clinical use. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):21-31

Acute stroke is the second leading cause of death and the third leading cause of disability in the world. Ischemic stroke (IS) the most common type of stroke. In acute cerebral ischemia, damage to the brain tissue is complex and includes blood-brain barrier (BBB) dysfunction, neuroinflammation, oxidative stress, activation of intracellular and extracellular signaling pathways, expression of neurotoxic agents, excitotoxicity, and apoptosis. In acute IS, reperfusion therapy (RT), is one of the most prominent treatment options. Most of the randomized clinical trials demonstrated the efficacy and safety of RT. The use of novel neuroimaging techniques (CT-perfusion and new MRI modalities) significantly expanded the RT selection criteria in patients with IS. One of the possible ways to further expand the RT is to combine it with neurocytoprotection. According to many researchers, this could potentially significantly improve the efficacy and safety of RT. This opinion is based on the concept of preserving brain tissue in the ischemic penumbra region. The aim of this review was to analyze the current trials of neurocytoprotection in combination with RT in IS patients.

Keywords:

ischemic stroke
reperfusion therapy
intravenous thrombolysis
mechanical thrombectomy
reperfusion injury
neuroprotection
cytoprotection
neurocytoprotection

Authors:

Shchukin I.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Koltsov I.A.

Pirogov Russian National Research Medical University (Pirogov University);
Federal Center of Brain Research and Neurotechnologies

Fidler M.S.

Pirogov Russian National Research Medical University (Pirogov University)

Glukhareva A.P.

Pirogov Russian National Research Medical University (Pirogov University)

Received:

12.12.2024

Accepted:

13.12.2024

List of references:

  1. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795-820.  https://doi.org/10.1016/S1474-4422(21)00252-0
  2. Scott CA, Li L, Rothwell PM. Diverging temporal trends in stroke incidence in younger vs older people: a systematic review and meta-analysis. JAMA Neurol. 2022;79(10):1036-1048. https://doi.org/10.1001/jamaneurol.2022.1520
  3. Yperzeele L, Shoamanesh A, Venugopalan YV, et al. Key design elements of successful acute ischemic stroke treatment trials. Neurol Res Pract. 2023;5(1):1.  https://doi.org/10.1186/s42466-022-00221-9
  4. del Zoppo GJ, Sharp FR, Heiss W-D, et al. Heterogeneity in the penumbra. J Cereb Blood Flow Metab. 2011;31(9):1836-1851. https://doi.org/10.1038/jcbfm.2011.93
  5. Symon L. Flow thresholds in brain ischaemia and the effects of drugs. Br J Anaesth. 1985;57(1):34-43.  https://doi.org/10.1093/bja/57.1.34
  6. Schaeffer S, Iadecola C. Revisiting the neurovascular unit. Nat Neurosci. 2021;24(9):1198. https://doi.org/10.1038/s41593-021-00904-7
  7. Attwell D, Buchan AM, Charpak S, et al. Glial and neuronal control of brain blood flow. Nature. 2010;468(7321):232-243.  https://doi.org/10.1038/nature09613
  8. Claassen JAHR, Thijssen DHJ, Panerai RB, et al. Regulation of cerebral blood flow in humans: physiology and clinical implications of autoregulation. Physiol Rev. 2021;101(4):1487-1559. https://doi.org/10.1152/physrev.00022.2020
  9. Wu L, Wu W, Tali ET, et al. Oligemia, penumbra, infarction: understanding hypoperfusion with neuroimaging. Neuroimaging Clin N Am. 2018;28(4):599-609.  https://doi.org/10.1016/j.nic.2018.06.013
  10. van Putten MJAM, Fahlke C, Kafitz KW, et al. Dysregulation of astrocyte ion homeostasis and its relevance for stroke-induced brain damage. Int J Mol Sci. 2021;22(11):5679. https://doi.org/10.3390/ijms22115679
  11. Ludhiadch A, Sharma R, Muriki A, et al. Role of calcium homeostasis in ischemic stroke: a review. CNS Neurol Disord Drug Targets. 2022;21(1):52-61.  https://doi.org/10.2174/1871527320666210212141232
  12. Shen Z, Xiang M, Chen C, et al. Glutamate excitotoxicity: Potential therapeutic target for ischemic stroke. Biomed Pharmacother. 2022;151:113125. https://doi.org/10.1016/j.biopha.2022.113125
  13. Martynov MYu, Zhuravleva MV, Vasyukova NS, et al. Oxidative stress in the pathogenesis of stroke and its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(1):16-27. (In Russ.). https://doi.org/10.17116/jnevro202312301116
  14. Wang Y, Hong F, Yang S. Roles of nitric oxide in brain ischemia and reperfusion. Int J Mol Sci. 2022;23(8):4243. https://doi.org/10.3390/ijms23084243
  15. Chen X, Chen H, Xu M, et al. Targeting reactive nitrogen species: a promising therapeutic strategy for cerebral ischemia-reperfusion injury. Acta Pharmacol Sin. 2013;34(1):67-77.  https://doi.org/10.1038/aps.2012.82
  16. Yu H, Chen X, Guo X, et al. The clinical value of serum xanthine oxidase levels in patients with acute ischemic stroke. Redox Biol. 2023;60:102623. https://doi.org/10.1016/j.redox.2023.102623
  17. Koltsov IA, Martynov MYu, Yasamanova AN, et al. Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2021;13(1S):62-68. (In Russ.). https://doi.org/10.14412/2074-2711-2021-1S-62-68
  18. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta. 2010;1802(1):80-91.  https://doi.org/10.1016/j.bbadis.2009.09.003
  19. Tuo Q-Z, Zhang S-T, Lei P. Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications. Med Res Rev. 2022;42(1):259-305.  https://doi.org/10.1002/med.21817
  20. Jiang X, Andjelkovic AV, Zhu L, et al. Blood-brain barrier dysfunction and recovery after ischemic stroke. Prog Neurobiol. 2018;163-164:144-171.  https://doi.org/10.1016/j.pneurobio.2017.10.001
  21. Koltsov IA, Shchukin IA, Chubykin VI, Fidler MS. Neuroinflammation and thromboinflammation in cerebrovascular disease and vascular cognitive impairment. Terapiya. 2022; 8(9):61-66. (In Russ.). https://doi.org/10.18565/therapy.2022.9.75-81
  22. Jurcau A, Simion A. Neuroinflammation in cerebral ischemia and ischemia/reperfusion injuries: from pathophysiology to therapeutic strategies. Int J Mol Sci. 2021;23(1):14.  https://doi.org/10.3390/ijms23010014
  23. Zhao X, Wang H, Sun G, et al. Neuronal interleukin-4 as a modulator of microglial pathways and ischemic brain damage. J Neurosci. 2015;35(32): 11281-11291. https://doi.org/10.1523/JNEUROSCI.1685-15.2015
  24. Gu W, Brännström T, Jiang W, et al. Vascular endothelial growth factor A and C protein up-regulation and early angiogenesis in a rat photothrombotic ring stroke model with spontaneous reperfusion. Acta Neuropathol (Berl). 2001;102(3):216-226.  https://doi.org/10.1007/s004010100370
  25. Greenberg DA, Jin K. Vascular endothelial growth factors (VEGFs) and stroke. Cell Mol Life Sci. 2013;70(10):1753-1761. https://doi.org/10.1007/s00018-013-1282-8
  26. Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion. J Am Med Assoc. 1958;167(14):1705-1709. https://doi.org/10.1001/jama.1958.02990310011002
  27. Gusev EI, Martynov MYu, Iasamanova AN, et al. Thrombolytic therapy of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(12-2):4-14. (In Russ.). https://doi.org/10.17116/jnevro20181181224
  28. Meyer JS, Gilroy J, Barnhart MI, Johnson JF. Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology. 1963;13:927-937.  https://doi.org/10.1212/wnl.13.11.927
  29. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke. 1976;7(2):135-142.  https://doi.org/10.1161/01.str.7.2.135
  30. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42(5):976-982.  https://doi.org/10.1212/wnl.42.5.976
  31. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587. https://doi.org/10.1056/NEJM199512143332401
  32. Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Stroke. 2000;31(4):811-816.  https://doi.org/10.1161/01.str.31.4.811
  33. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282(21):2019-2026. https://doi.org/10.1001/jama.282.21.2019
  34. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245-1251. https://doi.org/10.1016/s0140-6736(98)08020-9
  35. Multicenter Acute Stroke Trial — Europe Study Group, Hommel M, Cornu C, Boutitie F, Boissel JP. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med. 1996;335(3):145-150.  https://doi.org/10.1056/NEJM199607183350301
  36. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.  https://doi.org/10.1016/S0140-6736(04)15692-4
  37. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329. https://doi.org/10.1056/NEJMoa0804656
  38. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66-73.  https://doi.org/10.1161/01.STR.0000149938.08731.2c
  39. Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141-150.  https://doi.org/10.1016/S1474-4422(08)70267-9
  40. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227-1231. https://doi.org/10.1161/01.STR.0000217403.66996.6d
  41. Thomalla G, Simonsen CZ, Boutitie F, et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611-622.  https://doi.org/10.1056/NEJMoa1804355
  42. Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795-1803. https://doi.org/10.1056/NEJMoa1813046
  43. Palaiodimou L, Katsanos AH, Turc G, et al. Tenecteplase vs Alteplase in acute ischemic stroke within 4.5 hours: a systematic review and meta-analysis of randomized trials. Neurology. 2024;103(9):e209903. https://doi.org/10.1212/WNL.0000000000209903
  44. Gusev EI, Martynov MY, Nikonov AA, et al. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset In Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021;20(9): 721-728.  https://doi.org/10.1016/S1474-4422(21)00210-6
  45. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA. 1999;282(21):2003-2011. https://doi.org/10.1001/jama.282.21.2003
  46. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke. 2005;36(7):1432-1438. https://doi.org/10.1161/01.STR.0000171066.25248.1d
  47. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009;40(8):2761-2768. https://doi.org/10.1161/STROKEAHA.108.544957
  48. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet. 2012;380(9849):1231-1240. https://doi.org/10.1016/S0140-6736(12)61299-9
  49. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet. 2012;380(9849): 1241-1249. https://doi.org/10.1016/S0140-6736(12)61384-1
  50. Berkhemer OA, Fransen PSS, Beumer D, et al. A Randomized Trial of Intraarterial Treatment for Acute Ischemic Stroke. N Engl J Med. 2015; 372(1):11-20.  https://doi.org/10.1056/NEJMoa1411587
  51. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8): 708-718.  https://doi.org/10.1056/NEJMoa1713973
  52. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11-21.  https://doi.org/10.1056/NEJMoa1706442
  53. Kolahchi Z, Rahimian N, Momtazmanesh S, et al. Direct mechanical thrombectomy versus prior bridging intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis. Life Basel Switz. 2023;13(1):185.  https://doi.org/10.3390/life13010185
  54. Yang P, Zhang Y, Zhang L, et al. Endovascular thrombectomy with or without intravenous alteplase in acute stroke. N Engl J Med. 2020;382(21): 1981-1993. https://doi.org/10.1056/NEJMoa2001123
  55. LeCouffe NE, Kappelhof M, Treurniet KM, et al. A randomized trial of intravenous alteplase before endovascular treatment for stroke. N Engl J Med. 2021;385(20):1833-1844. https://doi.org/10.1056/NEJMoa2107727
  56. Yoshimura S, Sakai N, Yamagami H, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med. 2022;386(14):1303-1313. https://doi.org/10.1056/NEJMoa2118191
  57. Sarraj A, Hassan AE, Abraham MG, et al. Trial of endovascular thrombectomy for large ischemic strokes. N Engl J Med. 2023;388(14):1259-1271. https://doi.org/10.1056/NEJMoa2214403
  58. Huo X, Ma G, Tong X, et al. Trial of endovascular therapy for acute ischemic stroke with large infarct. N Engl J Med. 2023;388(14):1272-1283. https://doi.org/10.1056/NEJMoa2213379
  59. Bendszus M, Fiehler J, Subtil F, et al. Endovascular thrombectomy for acute ischaemic stroke with established large infarct: multicentre, open-label, randomised trial. Lancet. 2023;402(10414):1753-1763. https://doi.org/10.1016/S0140-6736(23)02032-9
  60. Writing Committee for the TESLA Investigators, Yoo AJ, Zaidat OO, et al. Thrombectomy for Stroke With Large Infarct on Noncontrast CT: The TESLA randomized clinical trial. JAMA. 2024;332(16):1355-1366. https://doi.org/10.1001/jama.2024.13933
  61. Costalat V, Jovin TG, Albucher JF, et al. Trial of thrombectomy for stroke with a large infarct of unrestricted size. N Engl J Med. 2024;390(18): 1677-1689. https://doi.org/10.1056/NEJMoa2314063
  62. Nour M, Scalzo F, Liebeskind DS. Ischemia-reperfusion injury in stroke. Interv Neurol. 2013;1(3-4):185-199.  https://doi.org/10.1159/000353125
  63. Sperring CP, Savage WM, Argenziano MG, et al. No-reflow post-recanalization in acute ischemic stroke: mechanisms, measurements, and molecular markers. Stroke. 2023;54(9):2472-2480. https://doi.org/10.1161/STROKEAHA.123.044240
  64. Lin L, Wang X, Yu Z. Ischemia-reperfusion injury in the brain: mechanisms and potential therapeutic strategies. Biochem Pharmacol (Los Angel). 2016;5(4):213.  https://doi.org/10.4172/2167-0501.1000213
  65. Kaur J, Zhao Z, Klein GM, et al. The neurotoxicity of tissue plasminogen activator? J Cereb Blood Flow Metab. 2004;24(9):945-963.  https://doi.org/10.1097/01.WCB.0000137868.50767.E8
  66. Shuaib A, Bornstein NM, Diener H-C, et al. Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial. Stroke. 2011;42(6):1680-1690. https://doi.org/10.1161/STROKEAHA.110.609933
  67. Hu W, Li W, Mangal R, et al. Normobaric hyperoxia (NBHO): an adjunctive therapy to cerebrovascular recanalization in ischemic stroke. Aging Dis. 2023;14(5):1483. https://doi.org/10.14336/AD.2023.0227
  68. Blauenfeldt RA, Hjort N, Valentin JB, et al. Remote ischemic conditioning for acute stroke: The RESIST randomized clinical trial. JAMA. 2023;330(13):1236-1246. https://doi.org/10.1001/jama.2023.16893
  69. Chen H-S, Cui Y, Li X-Q, et al. Effect of remote ischemic conditioning vs usual care on neurologic function in patients with acute moderate ischemic stroke: The RICAMIS randomized clinical trial. JAMA. 2022;328(7): 627-636.  https://doi.org/10.1001/jama.2022.13123
  70. Peng X, Wan Y, Liu W, et al. Protective roles of intra-arterial mild hypothermia and arterial thrombolysis in acute cerebral infarction. SpringerPlus. 2016;5(1):1988. https://doi.org/10.1186/s40064-016-3654-7
  71. Wu C, Zhao W, An H, et al. Safety, feasibility, and potential efficacy of intraarterial selective cooling infusion for stroke patients treated with mechanical thrombectomy. J Cereb Blood Flow Metab. 2018;38(12):2251-2260. https://doi.org/10.1177/0271678X18790139
  72. Pruvost-Robieux E, Benzakoun J, Turc G, et al. Cathodal transcranial direct current stimulation in acute ischemic stroke: pilot randomized controlled trial. Stroke. 2021;52(6):1951-1960. https://doi.org/10.1161/STROKEAHA.120.032056
  73. Ogawa A, Yoshimoto T, Kikuchi H, et al. Ebselen in acute middle cerebral artery occlusion: a placebo-controlled, double-blind clinical trial. Cerebrovasc Dis Basel Switz. 1999;9(2):112-118.  https://doi.org/10.1159/000015908
  74. Clark WM, Raps EC, Tong DC, et al. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke. 2000;31(6):1234-1239. https://doi.org/10.1161/01.str.31.6.1234
  75. Sacco RL, DeRosa JT, Haley EC, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285(13):1719-1728. https://doi.org/10.1001/jama.285.13.1719
  76. Lyden P, Jacoby M, Schim J, et al. The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results. Neurology. 2001;57(7):1199-1205. https://doi.org/10.1212/wnl.57.7.1199
  77. Krams M, Lees KR, Hacke W, et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke. 2003;34(11):2543-2548. https://doi.org/10.1161/01.STR.0000092527.33910.89
  78. Amaro S, Soy D, Obach V, et al. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke. 2007;38(7):2173-2175. https://doi.org/10.1161/STROKEAHA.106.480699
  79. Chamorro A, Amaro S, Castellanos M, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13(5):453-460.  https://doi.org/10.1016/S1474-4422(14)70054-7
  80. Chamorro Á, Amaro S, Castellanos M, et al. Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy. Int J Stroke Off J Int Stroke Soc. 2017;12(4):377-382.  https://doi.org/10.1177/1747493016684354
  81. Lees KR, Zivin JA, Ashwood T, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588-600.  https://doi.org/10.1056/NEJMoa052980
  82. Shuaib A, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562-571.  https://doi.org/10.1056/NEJMoa070240
  83. Diener H-C, Lees KR, Lyden P, et al. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke. 2008;39(6): 1751-1758. https://doi.org/10.1161/STROKEAHA.107.503334
  84. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12): e647-656.  https://doi.org/10.1161/STROKEAHA.109.564872
  85. Teal P, Davis S, Hacke W, et al. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT). Stroke. 2009;40(11):3518-3525. https://doi.org/10.1161/STROKEAHA.109.551382
  86. Heiss W-D, Brainin M, Bornstein NM, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636.  https://doi.org/10.1161/STROKEAHA.111.628537
  87. Lang W, Stadler CH, Poljakovic Z, Fleet D, Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013;8(2):95-104.  https://doi.org/10.1111/j.1747-4949.2012.00901.x
  88. Khasanova DR, Kalinin MN. Cerebrolysin as an early add-on to reperfusion therapy: risk of hemorrhagic transformation after ischemic stroke (CEREHETIS), a prospective, randomized, multicenter pilot study. BMC Neurol. 2023;23(1):121.  https://doi.org/10.1186/s12883-023-03159-w
  89. Chefranova ZhYu, Makotrova TA, Udachin VA, Koledintseva EV. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(4):49-52. (In Russ.).
  90. Stakhovskaya LV, Shamalov NA, Khasanova DR, et al. Results of a randomized double blind multicenter placebo-controlled, in parallel groups trial of the efficacy and safety of prolonged sequential therapy with mexidol in the acute and early recovery stages of hemispheric ischemic stroke (EPICA). S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(3-2):55-65. (In Russ.). https://doi.org/10.17116/jnevro20171173255-65
  91. Knni KS, Dyomin TV, Adeeva LB. Effect of mexidol on the efficiency of intravenous thrombolytic therapy for ischemic stroke during the therapeutic window. Neurology, neuropsychiatry, psychosomatics. 2018;10(3):86-90. (In Russ.). https://doi.org/10.14412/2074-2711-2018-3-86-90
  92. Voznyuk IA, Kolomentsev SV, Morozova EM. The impact of therapy with Mexidol on neurological deficit and functional outcome in patients with ischemic stroke: a systematic review and meta-analysis. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12-2):49-60. (In Russ.). https://doi.org/10.17116/jnevro202312312249
  93. Kono S, Deguchi K, Morimoto N, et al. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan. J Stroke Cerebrovasc Dis. 2013;22(3):190-196.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2011.07.016
  94. Kono S, Deguchi K, Morimoto N, et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. J Stroke Cerebrovasc Dis. 2013;22(7):1175-1183. https://doi.org/10.1016/j.jstrokecerebrovasdis.2013.02.010
  95. Wada T, Yasunaga H, Inokuchi R, et al. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator. J Neurol Sci. 2014;345(1-2):106-111.  https://doi.org/10.1016/j.jns.2014.07.018
  96. Lee X-R, Xiang G-L. Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator. Clin Neurol Neurosurg. 2018;167:157-161.  https://doi.org/10.1016/j.clineuro.2018.02.026
  97. Enomoto M, Endo A, Yatsushige H, et al. Clinical effects of early edaravone use in acute ischemic stroke patients treated by endovascular reperfusion therapy. Stroke. 2019;50(3):652-658.  https://doi.org/10.1161/STROKEAHA.118.023815
  98. Zhao K, Li G-Z, Nie L-Y, et al. Edaravone for acute ischemic stroke: a systematic review and meta-analysis. Clin Ther. 2022;44(12):e29-e38.  https://doi.org/10.1016/j.clinthera.2022.11.005
  99. Ginsberg MD, Palesch YY, Hill MD, et al. High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013;12(11):1049-1058. https://doi.org/10.1016/S1474-4422(13)70223-0
  100. Saver JL, Starkman S, Eckstein M, et al. Prehospital Use of Magnesium Sulfate as Neuroprotection in Acute Stroke. N Engl J Med. 2015;372(6):528-536.  https://doi.org/10.1056/NEJMoa1408827
  101. Woodhouse L, Scutt P, Krishnan K, et al. Effect of Hyperacute Administration (Within 6 Hours) of Transdermal Glyceryl Trinitrate, a Nitric Oxide Donor, on Outcome After Stroke: Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke (ENOS) Trial. Stroke. 2015;46(11):3194-3201. https://doi.org/10.1161/STROKEAHA.115.009647
  102. Zhu Z, Fu Y, Tian D, et al. Combination of the immune modulator Fingolimod with Alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132(12):1104-1112. https://doi.org/10.1161/CIRCULATIONAHA.115.016371
  103. Tian D-C, Shi K, Zhu Z, et al. Fingolimod enhances the efficacy of delayed Alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow. Ann Neurol. 2018;84(5):717-728.  https://doi.org/10.1002/ana.25352
  104. Montaner J, Bustamante A, García-Matas S, et al. Combination of Thrombolysis and Statins in Acute Stroke Is Safe: Results of the STARS Randomized Trial (Stroke Treatment With Acute Reperfusion and Simvastatin). Stroke. 2016;47(11):2870-2873. https://doi.org/10.1161/STROKEAHA.116.014600
  105. Wahlgren N, Thorén M, Höjeberg B, et al. Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis. J Intern Med. 2017;281(3):273-283.  https://doi.org/10.1111/joim.12576
  106. Wang X-H, You Y-P. Epigallocatechin Gallate Extends Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment for Brain Ischemic Stroke: A Randomized Double-Blind and Placebo-Controlled Trial. Clin Neuropharmacol. 2017;40(1):24-28.  https://doi.org/10.1097/WNF.0000000000000197
  107. Fraser JF, Maniskas M, Trout A, et al. Intra-arterial verapamil post-thrombectomy is feasible, safe, and neuroprotective in stroke. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab. 2017;37(11):3531-3543. https://doi.org/10.1177/0271678X17705259
  108. Elkins J, Veltkamp R, Montaner J, et al. Safety and efficacy of Natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017;16(3):217-226.  https://doi.org/10.1016/S1474-4422(16)30357-X
  109. Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology. 2020;95(8):e1091-e1104. https://doi.org/10.1212/WNL.0000000000010038
  110. Lyden P, Pryor KE, Coffey CS, et al. Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke. Ann Neurol. 2019;85(1):125-136.  https://doi.org/10.1002/ana.25383
  111. Culp WC, Onteddu SS, Brown A, et al. Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Randomized and Controlled Dose-Escalation Trial. J Vasc Interv Radiol JVIR. 2019;30(8):1244-1250.e1.  https://doi.org/10.1016/j.jvir.2019.04.020
  112. Kim JS, Lee KB, Park J-H, et al. Safety and Efficacy of Otaplimastat in Patients with Acute Ischemic Stroke Requiring tPA (SAFE-TPA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Ann Neurol. 2020;87(2):233-245.  https://doi.org/10.1002/ana.25644
  113. Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet Lond Engl. 2020;395(10227):878-887.  https://doi.org/10.1016/S0140-6736(20)30258-0
  114. Modrau B, Andersen G, Mikkelsen IK, et al. Theophylline as an Add-On to Thrombolytic Therapy in Acute Ischemic Stroke: A Randomized Placebo-Controlled Trial. Stroke. 2020;51(7):1983-1990. https://doi.org/10.1161/STROKEAHA.119.027446
  115. Hong JM, Lee JS, Lee Y-B, et al. Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial. Stroke. 2022;53(11):3250-3259. https://doi.org/10.1161/STROKEAHA.122.039649
  116. Wang A, Jia B, Zhang X, et al. Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Neurol. 2023;80(8):851-859.  https://doi.org/10.1001/jamaneurol.2023.1871
  117. Hernández-Jiménez M, Abad-Santos F, Cotgreave I, et al. Safety and Efficacy of ApTOLL in Patients With Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial. JAMA Neurol. 2023;80(8):779-788.  https://doi.org/10.1001/jamaneurol.2023.1660
  118. Godunova AR, Rakhimova AA, Leontyeva OI, et al. An influence of submaximal (submineximal) doses of mexidol on oxidant stress and inflammation in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(2):27-30. (In Russ.). https://doi.org/10.17116/jnevro20181182127-30
  119. Belkin AA, Belkin VA, Vasilchenko IE, Pinchuk EA. Results of a cohort single-center randomized study of the modulating effect of the drug Mexidol in the rehabilitation of patients who suffered acute cerebral insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(4):108-117. (In Russ.). https://doi.org/10.17116/jnevro2024124041108
  120. Shchul’kin AV, Abalenikhina YuV, Anan’eva PD, Yakusheva EN. Antioksidantnaya aktivnost’ i toksichnost’ etilmetilgidroksipiridina suktsinata i edaravona v eksperimente in vitro. Eksperimental’naya i klinicheskaya farmakologiya. 2021;84(11):9-12. (In Russ.).
  121. Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15(3):222-229.  https://doi.org/10.1159/000069318
  122. Aoki J, Kimura K, Morita N, et al. YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy). Stroke. 2017;48(3):712-719.  https://doi.org/10.1161/STROKEAHA.116.015042
  123. Yamaguchi T, Awano H, Matsuda H, et al. Edaravone with and without.6 Mg/Kg alteplase within 4.5 hours after ischemic stroke: a prospective cohort study (PROTECT4.5). J Stroke Cerebrovasc Dis. 2017;26(4):756-765.  https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.10.011
  124. Fidalgo M, Ricardo Pires J, Viseu I, et al. Edaravone for acute ischemic stroke — Systematic review with meta-analysis. Clin Neurol Neurosurg. 2022;219:107299. https://doi.org/10.1016/j.clineuro.2022.107299
  125. Xu J, Wang A, Meng X, et al. Edaravone Dexborneol versus Edaravone alone for the treatment of acute ischemic stroke: a phase III, randomized, double-blind, comparative trial. Stroke. 2021;52(3):772-780.  https://doi.org/10.1161/STROKEAHA.120.031197
  126. Fu Y, Wang A, Tang R, et al. Sublingual Edaravone Dexborneol for the treatment of acute ischemic stroke: The TASTE-SL randomized clinical trial. JAMA Neurol. 2024;81(4):319-326.  https://doi.org/10.1001/jamaneurol.2023.5716
  127. Martynov MYu, Koplik EV, Shchukin IA, et al. Characteristics of serum albumin in patients with intracerebral hemorrhagic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(8 2):8-14. (In Russ.).
  128. Heiss W-D, Brainin M, Bornstein NM, Tuomilehto J, Hong Z, Cerebrolysin Acute Stroke Treatment in Asia (CASTA) Investigators. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636.  https://doi.org/10.1161/STROKEAHA.111.628537

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.